Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been assigned a consensus recommendation of “Hold” from the fifteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $469.50.

MEDP has been the topic of several research reports. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Mizuho boosted their price target on Medpace from $495.00 to $586.00 and gave the company an “outperform” rating in a research report on Monday. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and upped their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Finally, Robert W. Baird reaffirmed a “neutral” rating and issued a $547.00 price objective (up from $477.00) on shares of Medpace in a research note on Wednesday, July 8th.

Insider Transactions at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Medpace

Several institutional investors have recently bought and sold shares of MEDP. Dorsey Wright & Associates acquired a new stake in Medpace during the 3rd quarter valued at approximately $5,082,000. Allspring Global Investments Holdings LLC raised its position in shares of Medpace by 164.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock valued at $2,086,000 after purchasing an additional 2,274 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Medpace in the 4th quarter valued at approximately $4,084,000. Cerity Partners LLC boosted its stake in shares of Medpace by 41.0% during the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock valued at $45,478,000 after buying an additional 23,530 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in shares of Medpace by 24,930.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock valued at $56,936,000 after buying an additional 100,968 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Down 1.3%

NASDAQ:MEDP opened at $529.23 on Thursday. The company has a market cap of $15.11 billion, a P/E ratio of 33.26, a P/E/G ratio of 2.72 and a beta of 1.15. Medpace has a fifty-two week low of $306.70 and a fifty-two week high of $628.92. The firm’s 50 day moving average is $473.64 and its two-hundred day moving average is $494.66.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the previous year, the company earned $3.67 EPS. The business’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts forecast that Medpace will post 17.04 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.